Aurora A激酶与妇科肿瘤

doi:10.3760/cma.j.issn.1673-422X.2014.02.012

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (2): 117-120.doi: 10.3760/cma.j.issn.1673-422X.2014.02.012

Aurora A激酶与妇科肿瘤

王恺越, 周怀君

210029 南京医科大学鼓楼临床医学院

收稿日期:2013-09-14 修回日期:2013-11-20 出版日期:2014-02-08 发布日期:2014-01-26
通讯作者: 周怀君，E-mail:zhouhj2007@126.com E-mail:zhouhj2007@126.com

Aurora A kinase and gynecological tumors

Wang Kaiyue, Zhou Huaijun

Drum Tower Clinic Medical College, Nanjing Medical University, Nanjing 210029, China

Received:2013-09-14 Revised:2013-11-20 Online:2014-02-08 Published:2014-01-26
Contact: Zhou Huaijun E-mail:zhouhj2007@126.com

摘要/Abstract

摘要： Aurora A是调控细胞周期有序进展的重要丝/苏氨酸激酶，严格依赖细胞周期参与细胞的有丝分裂进程。AURKA基因的单核苷酸多态性(SNP)及其编码产物Aurora A激酶的异常表达与卵巢癌、子宫内膜癌、宫颈癌及子宫肉瘤等妇科肿瘤的形成、发展和预后密切相关，显示Aurora A已成为妇科肿瘤靶向治疗的理想靶点。

关键词: 卵巢肿瘤, 子宫内膜肿瘤, 宫颈肿瘤, Aurora A激酶

Abstract: Aurora A is a key serine/threonine kinase regulating cell cycle, which is involved in various procedures of mitosis, strictly depending on cell cycle. The single nucleotide polymorphisms (SNP) of AURKA gene and the aberrant expression of its encoding product Aurora A kinase are often closely related with the tumorigenesis, progression and prognosis of gynecological tumors, such as ovarian cancer, endometrial cancer, cervical cancer and sarcoma of uterus. Aurora A has become an ideal target for the targeted therapy of gynecological tumors.

Key words: Ovarian neoplasms, Endometrial neoplasms, Cervical , neoplasms, Aurora A kinase

王恺越, 周怀君. Aurora A激酶与妇科肿瘤[J]. 国际肿瘤学杂志, 2014, 41(2): 117-120.

Wang Kaiyue, Zhou Huaijun. Aurora A kinase and gynecological tumors[J]. Journal of International Oncology, 2014, 41(2): 117-120.

参考文献

［1］ Vader G, Lens SM. The Aurora kinase family in cell division and cancer［J］. Biochim Biophys Acta, 2008, 1786(1): 60-72. ［2］ Karthigeyan D, Prasad SB, Shandilya J, et al. Biology of Aurora A kinase: implications in cancer manifestation and therapy［J］. Med Res Rev, 2011, 31(5): 757-793. ［3］ Nikonova AS, Astsaturov I, Serebriiskii IG, et al. Aurora A kinase (AURKA) in normal and pathological cell division［J］. Cell Mol Life Sci, 2013, 70(4): 661-687. ［4］ Zheng L, Song A, Ruan Y, et al. Genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 are associated with ovarian cancer susceptibility among Chinese Han women［J］. Cancer Epidemiol, 2013, 37(5): 639-646. ［5］ EwartToland A, Dai Q, Gao YT, et al. AuroraA/STK15 T+91A is a general low penetrance cancer susceptibility gene: a metaanalysis of multiple cancer types［J］. Carcinogenesis, 2005, 26(8): 1368-1373. ［6］ Shi H, Bevier M, Johansson R, et al. Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome［J］. Breast Cancer Res Treat, 2011, 130(3): 905-916. ［7］ Sun H, Bai J, Chen F, et al. Lack of an association between AURKA T91A polymorphisms and breast cancer: a metaanalysis involving 32 141 subjects［J］. Breast Cancer Res Treat, 2011, 125(1): 175-179. ［8］ Ramus SJ, Vierkant RA, Johnatty SE, et al. Consortium analysis of 7 candidate SNPs for ovarian cancer［J］. Int J Cancer, 2008, 123(2): 380-388. ［9］ Milam MR, Gu J, Yang H, et al. STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study［J］. Gynecol Onco, 2007, 107(1): 71-74. ［10］ Shan W, Akinfenwa PY, Savannah KB, et al. A smallmolecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma［J］. Clin Cancer Res, 2012, 18(12): 3352-3365. ［11］ Brewer Savannah KJ, Demicco EG, Lusby K, et al. Dual targeting of mTOR and auroraA kinase for the treatment of uterine Leiomyosarcoma［J］. Clin Cancer Res, 2012, 18(17): 4633-4645. ［12］ Zhang W, Wang J, Liu SJ, et al. Correlation between AuroraA expression and the prognosis of cervical carcinoma patients［J］. Acta Obstet Gynecol Scand, 2009, 88(5): 521-527. ［13］ Twu NF, Yuan CC, Yen MS, et al. Expression of Aurora kinase A and B in normal and malignant cervical tissue: high Aurora A kinase expression in squamous cervical cancer［J］. Eur J Obstet Gynecol Reprod Biol, 2009, 142(1): 57-63. ［14］ Lassus H, Staff S, Leminen A, et al. AuroraA overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma［J］. Gynecol Oncol, 2011, 120(1): 11-17. ［15］ Landen CN Jr, Lin YG, Immaneni A, et al. Overexpression of the centrosomal protein AuroraA kinase is associated with poor prognosis in epithelial ovarian cancer patients［J］. Clin Cancer Res, 2007, 13(14): 4098-4104. ［16］ Kulkarni AA, Loddo M, Leo E, et al. DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma［J. Clin Cancer Res, 2007, 13(20): 6153-6161. ［17］ Mendiola M, Barriuso J, MarioEnríquez A, et al. Aurora kinases as prognostic biomarkers in ovarian carcinoma［J］. Hum Pathol, 2009, 40(5): 631-638. ［18］ Lassmann S, Shen Y, Jütting U, et al. Predictive value of AuroraA/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy［J. Clin Cancer Res, 2007, 13(14): 4083-4091. ［19］ Yang F, Guo X, Yang G, et al. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma［J］. Mod Pathol, 2011, 24(6): 836845. ［20］ Matulonis UA, Sharma S, Ghamande S, et al. Phase Ⅱ study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinumresistant or refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma［J］. Gynecol Oncol, 2012, 127(1): 63-69. ［21］ Kurai M, Shiozawa T, Shih HC, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma［J］. Hum Pathol, 2005, 36(12): 1281-1288. ［22］ Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints［J］. J Clin Pathol, 2009, 62(9): 777785. ［23］ MorenoBueno G, SánchezEstévez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas［J］. Cancer Res, 2003, 63(18): 5697-5702. ［24］ Shimomura T, Hasako S, Nakatsuru Y, et al. MK5108, a highly selective AuroraA kinase inhibitor, shows antitumor activity alone and in combination with docetaxel［J］. Mol Cancer Ther, 2010, 9(1): 157-166. ［25］ Chefetz I, Holmberg JC, Alvero AB, et al. Inhibition of AuroraA kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway［J］. Cell Cycle, 2011, 10(13): 2206-2214.

[1]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[2]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[3]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[4]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[5]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[6]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[7]	凡梦思, 陆雅萍, 闫莉. 子宫内膜癌前哨淋巴结假阴性患者的临床病理特征分析[J]. 国际肿瘤学杂志, 2023, 50(5): 274-279.
[8]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[9]	杨洪娟, 孙云川, 何新颖, 毕建强, 肖丽. 子宫内膜中肾样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(4): 255-256.
[10]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[11]	吕璐, 孙鹏飞, 崔腾璐. 子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
[12]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[13]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[14]	史英侠, 胡莉钧, 于静萍. 免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.
[15]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.

Aurora A激酶与妇科肿瘤

Aurora A kinase and gynecological tumors

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价